IFNA17 and neoplasm: IFNα fused to rituximab demonstrated efficacy in lymphoma models though a molecular mechanism involving the binding of the construct to CD20 and the expression of IFNα receptor on tumor cells, suggesting a direct antitumor effect of this construct.